SCHEMBL7244674

SCHEMBL7244674

CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@H](n1c(C)nc3ccccc31)C2)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CCR5 P51681 19/20 1.00
▸ KCNH2 Q12809 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7244431 1.00 CCR5 (1.00) CCR5KCNH2
SCHEMBL7244425 1.00 CCR5 (1.00) CCR5KCNH2
SCHEMBL1574426 0.90 CCR5 (0.82) CCR5KCNH2
SCHEMBL1574425 0.90 CCR5 (0.82) CCR5KCNH2
SCHEMBL7246681 0.90 CCR5 (0.82) CCR5KCNH2
SCHEMBL7244113 0.89 CCR5 (0.80) CCR5KCNH2
SCHEMBL1573831 0.89 CCR5 (1.00) CCR5KCNH2
SCHEMBL7244123 0.89 CCR5 (1.00) CCR5KCNH2
SCHEMBL1574000 0.89 CCR5 (0.81) CCR5KCNH2
SCHEMBL7241883 0.89 CCR5 (1.00) CCR5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190314371-A1 USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS PESTELL RICHARD G (US) 2019-10-17 — — US claimed
US-20170231991-A1 Use Of Modulators Of CCR5 In The Treatment Of Cancer And Cancer Metastasis NIH-DEITR 2017-08-17 — — US claimed
US-20130303512-A1 Use of modulators of CCR5 in the treatment of Cancer and cancer metastasis PESTELL, RICHARD G. 2013-11-14 — — US claimed
US-6586430-B1 Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders PFIZER INC. 2003-07-01 — — US claimed
US-20230364085-A1 USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS PESTELL RICHARD G (US) 2023-11-16 — — US disclosed
US-11633397-B2 Use of modulators of CCR5 in the treatment of cancer and cancer metastasis PESTELL RICHARD G (US) 2023-04-25 — — US disclosed
US-20200360380-A1 CANCERS EXPRESSING CCR5 AND METHODS OF TREATMENT OF SAME THOMAS JEFFERSON UNIVERSITY (US) 2020-11-19 — — US disclosed
US-20190314371-A1 USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS PESTELL RICHARD G (US) 2019-10-17 — — US disclosed
US-20180303830-A1 CANCERS EXPRESSING CCR5 AND METHODS OF TREATMENT OF SAME THOMAS JEFFERSON UNIVERSITY (US) 2018-10-25 — — US disclosed
US-20170231991-A1 Use Of Modulators Of CCR5 In The Treatment Of Cancer And Cancer Metastasis NIH-DEITR 2017-08-17 — — US disclosed
US-9453836-B2 Use of modulators of CCR5 in the treatment of cancer and cancer metastasis PESTELL, RICHARD G. 2016-09-27 — — US disclosed
US-20130303512-A1 Use of modulators of CCR5 in the treatment of Cancer and cancer metastasis PESTELL, RICHARD G. 2013-11-14 — — US disclosed
US-20010039026-A1 Assay method PFIZER INC. 2001-11-08 — — US disclosed
EP-1118858-A2 Assay method Pfizer Limited (GB) 2001-07-25 — — EP disclosed
Send feedback